Top

Published in:

01-02-2014

Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay

Authors: Wilmare Gouws, Elsabie Botha, Adele Visser

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2014

Abstract

The chromogenic FVIII assay is currently considered the gold standard for quantitation of factor VIII levels in both haemophilia A patients and as part of screening for thrombophilia. A method validation and evaluation of clinical utility within a routine diagnostic laboratory was undertaken by comparing the currently used one-stage assay to a commercially available chromogenic assay (Siemens, Johannesburg, South Africa). In total, 60 samples were included in this study to encompass the whole diagnostic range of the assay. Both low and high values showed very good correlation on linear regression analysis with correlation coeffients of 0.949 and 0.888 respectively. However, the lower detection limit of the Siemens Chromogenic assay was 1.5 IU/dL rendering it impossible to utilize in the setting of classifying a haemophilia A patient in terms of disease severity. Although the Siemens FVIII chromogenic assay shows excellent correlation to the currently used one-stage assay, the relatively high detection limit restrict implementation as a stand-alone assay in a routine diagnostic laboratory.

Chandler W, Ferrell C et al (2003) Comparison of three methods for mesauring factor VIII levels in plasma. Am J Clin Pathol 120:34–39PubMedCrossRef

Koster T, Blann A et al (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurance of deep-vein thrombosis. Lancet 345(8943):152–155PubMedCrossRef

Barrowcliffe T, Raut S et al (2002) Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization and recommendations. Semin Thromb Hemost 28(3):247–256PubMedCrossRef

Barrowcliffe T (1984) Methodology of the two-stage assay of Factor VIII (VIII:C). Scand J Haematol 33(Suppl 41):25–38

Over J (1984) Methodology of the one-stage assay of factor VIII (VIII:C). Scand J Haematol 33(Suppl 41):13–24

Rosen S, Friberger P et al (1986) A new chromogenic assay for determination of human factor VIII:C activity. College of American Pathologists, Skokie

Denson K, Biggs R (1976) Laboratory diagnosis, tests of clotting function and their standardization. Lippincott, Oxford

Peerlinck K, Jacquemin M (2010) Mild haemophilia: a disease with many faces and many unexpected pitfalls. Haemophilia 16(Suppl 5):100–106PubMedCrossRef

Hill N, Deam S et al (2005) Mutation analysis of 51 patients with haemophilia A: report of ten novel mutations an correlation between genotype and clinical phenotype. Haemophilia 11:13–141CrossRef

10.

Keeling D, Sukhu K et al (1999) Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His 1954—Leu substitutution in the factor VIII A3 domain. Br J Haematol 105:1123–1126PubMed

11.

Kemball-Cook G, Tuddenham E et al (1998) The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res 26:216–219PubMedCentralPubMedCrossRef

12.

Lyall H, Hill M et al (2008) Tyr346-Cys mutation results in factor VIII:C assay discrepancy and a normal bleeding phenotype—is this mild haemophilia A? Haemophilia 14:78–80PubMed

13.

Pipe S, Saenko E et al (2007) Haemophilia A mutations associated with 1-stage/2-stage activity discrepancy disrupt protein–protein interactions within the triplicated A domains of thrombin-activated factro VIIIa. Blood 97:685–697CrossRef

14.

Rudzki Z, Duncan E et al (1996) Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol 94:400–406PubMed

15.

Schwaab R, Oldenburg J et al (2000) Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694IIe) in a large Danish family. Br J Haematol 109(3):523–528PubMed

16.

Gilmore R, Harmon S et al (2010) Thrombin generation in haemophilia A patients with mutations causing factor VIII assay discrepancy. Haemophilia 16:671–674PubMed

17.

Mumford A, Laffan M et al (2002) A Tyr346–> Cys substitution in the interdomain acidic region a1 of factor VIII in an individual with factor VIII:C assay discrepancy. Br J Haematol 118(2):589–594PubMed

18.

Poulsen A, Pedersen L et al (2009) Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre. Haemophilia 15:285–289PubMedCrossRef

19.

ICH (1995) Validation of analytical procedures: text and methodology. The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH, Geneva

20.

Collazo V, Alonso C et al (2012) Validation of an automated chromogenic assay of potency of factor VIII in commercial concentrates. Int J Lab Hematol 35(1):38–45PubMedCrossRef

21.

White G, Rosendaal F et al (2001) Definitions in hemophilia. recommendations of the scientific subcommittee on FVIII and factor IX of the SCC and ISTH. Thromb Haemost 85:560PubMed

22.

Begbie M, Notley C et al (2000) The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost 84(2):216–222PubMed

23.

Noe D, Murphy P et al (1989) Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits. Am J Physiol 257(1):49–56

24.

Bjorkman S, Blanchette V et al (2010) Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost 8(4):730–736PubMedCentralPubMedCrossRef

25.

Hathaway, W., M. Christian, et al. (1983). “Variant mild haemophilia. Discrepancy in one stage and two stage factor VIII assays.” Thromb Haemost (Suppl 50): 357

26.

Parquet-Gernez A, Mazurier C et al (1988) Fuctional and immunological assays of FVIII in 133 haemophiliacs—characterization of a subgroup of patients with mild haemohilia A and descrepancy in 1- and 2-stage assays. Thromb Haemost 59:202–206PubMed

27.

Duncan E, Duncan B et al (1994) Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of paitents with haemophilia A. Br J Haematol 87:846–848PubMed

28.

Goodeve A, Peake I (2003) The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Semin Thromb Hemost 29:23–30PubMedCrossRef

29.

Mazurier C, Gaucher C et al (1997) Mutations in the FVIII gene in seven families with haemophilia A. Br J Haematol 96:426–427PubMed

30.

Roelse, J., R. de-Laaf, et al. (1999). Altered sensitivity towards factor IXa explains assay discrepancies in plasma of haemophilia A patients with a Glu720–> Lys substitution in factor VIII. Thromb Haemost. doi:10.1111/j.1365-2141.2007.06935.x

31.

Goodeve, A., J. Hinks, et al. (2001). Unusual discrepant factor VIII:C assays in haemophilia A patients iwth Tyr346Cys and Glu321Lys FVIII gene mutations. Thromb Haemost. doi:10.1111/j.1365-2516.2011.02509.x

32.

Trossaert M, Boisseau P et al (2011) Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J Thromb Haemost 9:524–530PubMedCrossRef

33.

European Pharmacopoiea (2010) Assay of human coagulation factor VIII (01/2008:20704) and monograph human coagulation factor VIII (01/2010:0275). E. D. f. t. Q. o. M. HealthCare, Strassbourg

34.

Cid A, Calabuig M et al (2008) One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 14:1049–1054PubMedCrossRef

35.

Plug I, Mauser-Bunchoten E et al (2006) Bleeding in carriers of hemophilia. Blood 108(1):52–56PubMedCrossRef

36.

Verbruggen B, Meijer P et al (2008) Diagnosis of factor VIII deficiency. Haemophilia 14(Suppl 3):76–82PubMedCrossRef

Title: Method validation and clinical utility of chromogenic factor VIII assay compared to one-stage assay
Authors: Wilmare Gouws
Elsabie Botha
Adele Visser
Publication date: 01-02-2014
Publisher: Springer US
Published in: Journal of Thrombosis and Thrombolysis / Issue 2/2014
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-013-0910-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Evidence behind quality of care measures for venous thromboembolism and atrial fibrillation

Warfarin use in atrial fibrillation patients at low risk for stroke: analysis of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2)

Thrombosis on a mechanical mitral valve anticoagulated with dabigatran

Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation

Short-term central venous catheter complications in patients with sickle cell disease who undergo apheresis

The pharmacology of novel oral anticoagulants

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials